To validate this hypothesis, TNBC cells – over-expressing or not TRF2 – were treated with a number of antineoplastic agents commonly used in BC therapy and drug sensitivity was evaluated both in vitro and in experimental in vivo models. Here, TERF2 is linked to breast cancer.